Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bumper Crop Of Consumer Health Deals Expected As Large Firms Prune Portfolios

This article was originally published in The Tan Sheet

Executive Summary

A surge of M&A transactions in 2014 and early 2015 likely will result in brand spin-offs as big firms focus on core elements of their portfolios, consumer health market experts say. Fragmentation in the market, low interest rates and participation by private equity will drive more, though likely smaller deals.

You may also be interested in...

P&G’s Potential Personal Care Brands Divestment Sparks Analyst Support

P&G could divest, at one fell swoop, prestige fragrances, makeup brands Cover Girl and Max Factor, and salon and small retail hair-care brands, analysts speculate, following reports that the firm is exploring a possible sale or IPO of personal care and beauty brands en masse.

H.I.G.’s Capstone Puts Customers First With Custom Formulations

The private equity firm’s H.I.G. Growth Partners capital investment affiliate merges two of its businesses, Integrity Nutraceuticals and Cornerstone Research & Development, into Capstone Nutrition. CEO Greg Horn says “we really occupy a niche” in “a pretty fragmented industry” with custom formulations for every product.

Pfizer Reorganizes Internally, Closer To Decision On Splitting Business

Consumer health products are grouped with vaccines and oncology drugs in Pfizer’s internal reorganization that takes effect in January 2014. Pfizer’s realignment into three organizations represents a step in the firm’s multi-year deliberation over whether to split its business.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts